Recurrent Inflammatory Flares in HIV-Infected Patients: Consider Castleman Disease!

Por Jegerlehner, Sabrina, Rauch, Andri, Novak, Urban
Publicado no J Investig Med High Impact Case Rep (2017)

Molecular modulation of autophagy: New venture to target resistant cancer stem cells

Por Mandhair, Harpreet K, Arambasic, Miroslav, Novak, Urban, Radpour, Ramin
Publicado no World J Stem Cells (2020)

Mineral Deposition in Bacteria-Filled and Bacteria-Free Calcium Bodies in the Crustacean Hyloniscus riparius (Isopoda: Oniscidea)

Por Vittori, Miloš, Rozman, Alenka, Grdadolnik, Jože, Novak, Urban, Štrus, Jasna
Publicado em 2013

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients

Por Shumilov, Evgenyi, Novak, Urban, Jeker, Barbara, Mansouri Taleghani, Behrouz, Bacher, Ulrike, Pabst, Thomas
Publicado no Hemasphere (2019)

HHV-8 seroprevalence: a global view

Por Rohner, Eliane, Wyss, Natascha, Trelle, Sven, Mbulaiteye, Sam M, Egger, Matthias, Novak, Urban, Zwahlen, Marcel, Bohlius, Julia
Publicado em 2014

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients

Por Schnell, Bianca R., Seipel, Katja, Bacher, Ulrike, Jeker, Barbara, Mueller, Beatrice U., Banz, Yara, Novak, Urban, Pabst, Thomas
Publicado no Hemasphere (2019)

HIV and human herpesvirus 8 co-infection across the globe: systematic review and meta-analysis

Por Rohner, Eliane, Wyss, Natascha, Heg, Zina, Faralli, Zully, Mbulaiteye, Sam M., Novak, Urban, Zwahlen, Marcel, Egger, Matthias, Bohlius, Julia
Publicado no Int J Cancer (2015)

Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leuk...

Por de Benito, Alvaro de Santiago, Jeker, Barbara, Gfeller, Eva, Porret, Naomi, Banz, Yara, Novak, Urban, Bacher, Ulrike, Pabst, Thomas
Publicado no Haematologica (2020)

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use

Por Bacher, Ulrike, Shumilov, Evgenii, Flach, Johanna, Porret, Naomi, Joncourt, Raphael, Wiedemann, Gertrud, Fiedler, Martin, Novak, Urban, Amstutz, Ursula, Pabst, Thomas
Publicado no Blood Cancer J (2018)

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells

Por Burkhard, Regula, Keller, Irene, Arambasic, Miroslav, Juskevicius, Darius, Tzankov, Alexandar, Lundberg, Pontus, Bruggmann, Rémy, Dirnhofer, Stephan, Radpour, Ramin, Novak, Urban
Publicado no Haematologica (2019)

CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas

Por Juilland, Mélanie, Gonzalez, Montserrat, Erdmann, Tabea, Banz, Yara, Jevnikar, Zala, Hailfinger, Stephan, Tzankov, Alexandar, Grau, Michael, Lenz, Georg, Novak, Urban, Thome, Margot
Publicado no Blood (2016)

Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer – a retrospective study

Por Cihoric, Nikola, Tsikkinis, Alexandros, Vlaskou Badra, Eugenia, Glatzer, Markus, Novak, Urban, Scherz, Amina, Shelan, Mohamed, Soldatovic, Ivan, Yojena, Chittazhathu Kurian Kuruvilla, Aebersold, Daniel M., Lössl, Kristina
Publicado no Radiat Oncol (2017)

BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma

Por Saito, Masumichi, Novak, Urban, Piovan, Erich, Basso, Katia, Sumazin, Pavel, Schneider, Christof, Crespo, Marta, Shen, Qiong, Bhagat, Govind, Califano, Andrea, Chadburn, Amy, Pasqualucci, Laura, Dalla-Favera, Riccardo
Publicado em 2009

Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

Por Herbrand, Amanda Katherina, Schmitt, Andreas Michael, Briel, Matthias, Diem, Stefan, Ewald, Hannah, Hoogkamer, Anouk, Joerger, Markus, Mc Cord, Kimberly Alba, Novak, Urban, Sricharoenchai, Sirintip, Hemkens, Lars G, Kasenda, Benjamin
Publicado no ESMO Open (2019)

The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas

Por Novak, Urban, Rinaldi, Andrea, Kwee, Ivo, Nandula, Subhadra V., Rancoita, Paola M. V., Compagno, Mara, Cerri, Michaela, Rossi, Davide, Murty, Vundavalli V., Zucca, Emanuele, Gaidano, Gianluca, Dalla-Favera, Riccardo, Pasqualucci, Laura, Bhagat, Govind, Bertoni, Francesco
Publicado em 2009

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Por Driessen, Christoph, Müller, Rouven, Novak, Urban, Cantoni, Nathan, Betticher, Daniel, Mach, Nicolas, Rüfer, Axel, Mey, Ulrich, Samaras, Panagiotis, Ribi, Karin, Besse, Lenka, Besse, Andrej, Berset, Catherine, Rondeau, Stephanie, Hawle, Hanne, Hitz, Felicitas, Pabst, Thomas, Zander, Thilo
Publicado no Blood (2018)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Por Pestalozzi, Bernhard C., Tausch, Christoph, Dedes, Konstantin J., Rochlitz, Christoph, Zimmermann, Stefan, von Moos, Roger, Winterhalder, Ralph, Ruhstaller, Thomas, Mueller, Andreas, Buser, Katharina, Borner, Markus, Novak, Urban, Nussbaum, Catrina Uhlmann, Seifert, Bettina, Bigler, Martin, Bize, Vincent, Vilei, Simona Berardi, Rageth, Christoph, Aebi, Stefan
Publicado no BMC Cancer (2017)

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial

Por Benz, Rudolf, Arn, Kornelius, Andres, Martin, Pabst, Thomas, Baumann, Michael, Novak, Urban, Hitz, Felicitas, Hess, Urs, Zenhaeusern, Reinhard, Chalandon, Yves, Mey, Ulrich, Blum, Sabine, Rauch, Daniel, O'Meara Stern, Alix, Cantoni, Nathan, Bargetzi, Mario, Bianchi-Papina, Elena, Rossi, Davide, Passweg, Jakob, Lohri, Andreas, Berardi, Simona, Li, Qiyu, Feller, Anita, Stussi, Georg
Publicado no Blood Adv (2020)

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Por Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Publicado no Lancet Oncol (2019)